“Your sort of best step up from one half to two half to go from down low single to upload single life sciences. Call it $150 million.”

In context

“e really saying is the first half in the life science segment was down low singles. We expect the full year to be flat, so the second half needs to be up positive low singles. And what we're really seeing there is the impact of three factors. The first is and we're actually not assuming a significantly improved activity level. So in genomics, we expect to see better comps as an example. So in China, we're seeing it's incrementally firmer with some stimulus dollars following through. And then as you suggested, we have a number of new product introductions that are gaining track funnels here in the first half, including Ciox. And Beckman Coulter Life Sciences and some others. And so we expect those to gain traction here in the second half. Maybe to put some numbers around it for you, Tycho. Your sort of best step up from one half to two half to go from down low single to upload single life sciences. Call it $150 million. Roughly. And I think if you if you are kind of trying to bridge that I would say that genomics again, remember the first half, we had those two large customers really fall off. I think that's probably a third of it. I would say that we are assuming China, especially China and tools, with some comps, easier comps and a better funding environment is another third of it. And then lastly, you know, new products and kind of other things is the final third. So a third, a third, a third between China, genomics, new products, other. That's sort of what we're assuming and it baked into the model from StepUp. From one half to two half of roughly $150 million. Tycho Peterson: Okay. That's helpful. And then one quick follow-up sounds like you're not flagging any incremental headwinds on volume-based”